Drug intelligence / Profile preview

HeartReady

Development stage: Preclinical
Lead developer: BioCardia
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Percutaneous, Parenteral

Overview

HeartReady is an induced pluripotent stem cell (iPSC)-derived cell therapy consisting of mature human ventricular cardiomyocytes. Developed by Cardia Therapeutics, a subsidiary of CytoHub, the therapy is designed for myocardial repair and cell replacement in patients suffering from post-myocardial infarction (post-MI) scarring and ischemic heart failure. The therapeutic approach aims to restore cardiac function by engrafting functional, mature cardiomyocytes into the damaged myocardium to replace lost muscle tissue and improve overall heart contractility. As of the current pipeline disclosure, HeartReady is in the preclinical stage of development.

Brand names: HeartReady
Other names: HeartReady

Beyond the preview

Go deeper on HeartReady.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HeartReady.

Explore the full profile